Minoxidil is an orally potent long-acting direct vasodilator that selectively relaxes peripheral vascular smooth muscle cells, thereby decreasing the peripheral vascular resistance and reducing blood pressure (BP). 1 Around 30 years ago, uncontrolled paediatric studies showed that minoxidil is useful in achieving BP control in patients with refractory arterial hypertension. [2] [3] [4] Since the publication of these studies, there have been important changes regarding the definition and in the evaluation and treatment of hypertension in the paediatric population. 5 For example, according to the current guidelines, most of the concomitant antihypertensive drugs used in those studies are no longer recommended as first-line agents. 5 In addition, although minoxidil is still advised for the treatment of resistant hypertension, 5 there is a paucity of studies aimed at addressing the use of minoxidil combined with newer antihypertensive agents. Therefore, we summarize our experience in paediatric and young adult patients with asymptomatic secondary hypertension who were resistant to the treatment of hypertension as per the current recommendations, and in whom minoxidil was added to achieve target BP.
The clinical decision to start minoxidil was made on the basis that our patients exhibited refractory hypertension, which is defined as unsatisfactory BP control despite simultaneous treatment with three or more antihypertensive drugs of different classes in adequate doses. To titrate doses of minoxidil better and to monitor BP closely, all our patients were admitted to hospital. Pre-minoxidil therapy BP values presented herein are therefore the average of several readings taken from the right arm by an oscillometric device during awake, supine and rest states the day before minoxidil therapy was started. The target BP, while receiving minoxidil, was defined as the average of awake systolic and diastolic BP readings, also taken from the right arm in the supine position, p95th age-, sex-and heightmatched percentile of the adapted reference standard. 5 In the outpatient clinic, controlled BP, that is, BP values within the normotensive range while receiving antihypertensive therapy, was defined as the average of two systolic and diastolic BP readings, taken from the right arm in the sitting position, at least 1 min apart after X5 min of rest, p95th age-, sex-and height-matched percentile of the adapted reference standard. 5 In one patient aged 418 years, target BP and controlled BP were defined as systolic and diastolic BP values recorded as described above, p129 and 84 mm Hg, respectively. 6 When applied, ambulatory BP monitoring (ABPM) was performed as previously described. 7 Controlled ambulatory BP was defined either as mean systolic or mean diastolic 24-h BP values p95th adjusted height-and sex-related percentile or standard deviation scores (SDSs) p1.5, unless otherwise indicated. 8 Patients' clinical characteristics, including the effective daily dose of minoxidil to achieve the target BP, and duration of therapy are shown in Table 1 . During hospital stay, a consistent reduction in systolic and diastolic BP was observed in all patients within 5-8 days after commencement of minoxidil (Table 1) . In patient 2, however, further increase in the dose of antihypertensive agents, including minoxidil (up to 5 mg daily, that is, 0.2 mg kg À1 day À1 ), was necessary to maintain his BP within the normotensive range after hospital discharge. He was ultimately switched to an intensified haemodialysis of six sessions per week, 3 months after starting minoxidil therapy. Fluid overload due to ultrafiltration failure and no residual renal function were the causes of this modality change. Once haemodialysis became a regular procedure and response to antihypertensive therapy appeared to be optimal, doses of concomitant antihypertensive agents were decreased and minoxidil was gradually withdrawn. The results of his most recent ABPM, while receiving antihypertensive therapy based on b-blocker, angiotensinconverting enzyme inhibitor and calcium channel blocker, were as follows: 24-h BP, 106/70 mm Hg (SDS, 0.1/0.67); daytime BP, 111/76 mm Hg (SDS, À0.01/0.6); and nighttime BP, 95/59 mm Hg (SDS, 0.05/0.8), for systolic and diastolic BP, respectively.
In patient 1, concomitant antihypertensive agents were either reduced or discontinued after achieving sustained target BP. At the time of writing this letter, his antihypertensive treatment consisted of minoxidil, angiotensin-converting enzyme inhibitor and diuretic. His follow-up home systolic and diastolic BP values, measured on a daily basis before the start and after the disconnection of peritoneal dialysis, were consistently p95th age-, sex-and height-matched percentile of the adapted reference standard. 5 Patient 3 was admitted with advanced chronic renal failure within the context of progressive renal graft dysfunction. Haemodialysis was initiated 3 days after starting minoxidil treatment. He eventually underwent re-transplantation 5 months following the start of dialysis and was shortly thereafter transferred from paediatric to the adult transplant unit. He was maintained on minoxidil throughout the course of haemodialysis, which was withdrawn 14 months after kidney transplantation. His current antihypertensive therapy consists of a b-blocker, a calcium channel blocker, an angiotensin receptor blocker and a diuretic. The most recent ABPM, performed at the age of 21.3 years, showed the following controlled systolic and diastolic BP values: 24-h BP, 130/80 mm Hg; daytime BP, 133/ 84 mm Hg; and nighttime BP, 120/69 mm Hg. 6 All patients underwent a pre-treatment echocardiogram as evaluation for the presence of left ventricular hypertrophy (LVH), which was used as a surrogate marker of hypertensive end-organ damage. 9 Left ventricular mass was calculated as previously described. 10 Echocardiographic examinations were performed, when applicable, after the dialysis procedure. All measurements were performed by one investigator (GV) who was blinded to the patients' BP status. LVH was defined as left ventricular mass index (LVMI) 495th distribution percentile established in healthy children and adolescents. 11 In patient 3, who was aged 418 years, LVH was defined as LVMI 451 g m À2.7 . 12 Pre-minoxidil treatment and follow-up LVMIs are shown in Table 1 .
Overall, minoxidil has been well tolerated. Side effects were limited to hypertrichosis in all patients, which eventually disappeared once minoxidil was discontinued (patient 2 and patient 3). Hypertrichosis may, however, represent a limitation to the use of minoxidil in female patients. 1 After the start of minoxidil, none of the patients experienced reflex tachycardia (Table 1) , probably because of the concomitant use of a b-adrenergic blocker. 1 Following discontinuation of minoxidil therapy, neither patient 2 nor patient 3 experienced rebound hypertension. In patient 1, follow-up echocardiographic examination, which was performed during ongoing minoxidil therapy, showed no pericardial effusion, a potential side effect described with the use of minoxidil. minoxidil were provided, [2] [3] [4] it is apparent that our patients needed lower daily doses of minoxidil to achieve the target BP than in the previous investigations. It should also be noted that in the aforementioned studies target BP was defined at higher cut-off BP values than in our case series, which might imply that in these studies lower doses of minoxidil would have been sufficient to achieve controlled BP. We speculate that the differences in the dosage of minoxidil between previous studies and the present case series might rely on the fact that our patients received diverse concomitant antihypertensive drugs with complementary mechanisms of action. This may suggest that, when combined with newer antihypertensive agents, the use of lower doses of minoxidil might be equally effective in obtaining the target BP.
In conclusion, we observed that the addition of low doses of minoxidil to the currently recommended antihypertensive treatment can be remarkably useful in safely achieving sustained BP control in children and young adults with refractory hypertension secondary to renal disease.
